Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 2/20 | 0.72 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.55 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615009 | 1.00 | GGH (0.72) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL1374837 | 0.84 | GGH (1.00) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL1374839 | 0.84 | GGH (1.00) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL1376216 | 0.81 | GGH (0.69) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL1376219 | 0.81 | GGH (0.69) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| Glutamic Acid SCHEMBL18301536 | 0.79 | GRM8 (0.56) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| D-Glutamate SCHEMBL18301529 | 0.79 | GRM8 (0.56) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL28441053 | 0.79 | GGH (0.47) | GGHFOLH1NAALAD2 | |
| SCHEMBL14243858 | 0.79 | GGH (0.71) | GGHFOLH1NAALAD2RIMKLA | |
| SCHEMBL2368891 | 0.79 | GGH (0.71) | GGHFOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2002514157-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0957924-A4 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0957924-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-24 | — | — | EP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| CN-1230889-A | NAALADase compositions and methods for treating glutamate abnormalities and for producing neuronal activity in animals | GUILFORD PHARM INC (US) | 1999-10-06 | — | — | CN | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-20250360126-A1 | TARGETING AN ENZYME REQUIRED FOR ACUTE MYELOID LEUKEMIA | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2023239709-A2 | TARGETING AN ENZYME REQUIRED FOR ACUTE MYELOID LEUKEMIA | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-104174071-A | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNAT GMBH | 2014-12-03 | — | — | CN | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | GGH 54/4885FOLH1 9/4885NAALAD2 1/4885 |
| US-20250360126-A1 | TARGETING AN ENZYME REQUIRED FOR ACUTE MYELOID LEUKEMIA | GLUL, NPM1, TGM2 | GGH 10/4885FOLH1 36/4885NAALAD2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.